Triple
T17871350
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | John Maraganore |
E446842
|
entity |
| Predicate | associatedWith |
P37
|
FINISHED |
| Object | Alnylam Pharmaceuticals leadership team |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Alnylam Pharmaceuticals leadership team | Statement: [John Maraganore, associatedWith, Alnylam Pharmaceuticals leadership team]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Alnylam Pharmaceuticals leadership team Context triple: [John Maraganore, associatedWith, Alnylam Pharmaceuticals leadership team]
-
A.
Alnylam Pharmaceuticals
chosen
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
B.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
C.
Array BioPharma
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
-
D.
Gilead Sciences (board member)
Gilead Sciences is a major American biopharmaceutical company known for developing antiviral drugs, including treatments for HIV, hepatitis C, and other serious diseases.
-
E.
Editas Medicine
Editas Medicine is a biotechnology company focused on developing CRISPR-based gene-editing therapies to treat serious genetic diseases.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8b9f4c22c819093c2680434472894 |
completed | April 10, 2026, 8:51 a.m. |
| NER | Named-entity recognition | batch_69e49aa30ff8819090c51c1d7767e952 |
completed | April 19, 2026, 9:04 a.m. |
Created at: April 10, 2026, 10:18 a.m.